Bob Löwenberg
鲍勃·卢文伯格
MD, PhD
Emeritus Professor of Hematology血液学荣休教授
👥Biography 个人简介
Bob Löwenberg is one of the most influential hematologists in AML history, having shaped intensive chemotherapy protocols and led landmark trials addressing AML biology, treatment optimization, and care for older patients over five decades.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
AML Chemotherapy Optimization
Led the HOVON cooperative group in defining optimal induction and consolidation regimens for AML, and conducted seminal dose-escalation and schedule trials that refined global chemotherapy standards.
AML in Older Patients
Pioneered research on the distinct biology and treatment challenges of AML in patients over 60, including studies of low-intensity versus intensive therapy, informing individualized treatment selection.
Representative Works 代表性著作
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
New England Journal of Medicine (2009)
Demonstrated improved survival with higher daunorubicin dosing in older AML patients, changing induction chemotherapy practice internationally.
Acute Myeloid Leukemia
New England Journal of Medicine (1999)
Definitive review establishing foundational understanding of AML pathophysiology, classification, and treatment strategies referenced across two decades.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 鲍勃·卢文伯格 的研究动态
Follow Bob Löwenberg's research updates
留下邮箱，当我们发布与 Bob Löwenberg（Erasmus MC Rotterdam）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment